Elan shares take further hit amid fresh Tysabri concerns
Share prices in the Irish-based pharmaceutical company Elan fell further on the Dublin stock exchange today amid fresh fears about the multiple sclerosis drug Tysabri.
The fall followed concerns that a fourth patient in the United States may have contracted the potentially fatal brain disease PML after being treated with Tysabri.





